Analysts are intrested in these 5 stocks: ( (MBRX) ), ( (CNSP) ), ( (GLBE) ), ( (THC) ) and ( (SMMT) ). Here is a breakdown of their recent ratings and the rationale behind them.
Moleculin Biotech is generating buzz among investors as it secures capital to launch its P3 MIRACLE study for Annamycin in treating acute myeloid leukemia. Analyst Jason Mccarthy has upgraded the stock to a Buy, setting a 12-month price target of $4.00. The company has raised $9.3 million through favorable transactions, positioning it well for the upcoming study. The interim data expected in the second half of 2025 could significantly impact the stock’s performance, especially if Annamycin shows promising results compared to historical data.
CNS Pharmaceuticals faces a setback as its lead asset, Berubicin, failed to meet the primary endpoint in a Phase 2 glioblastoma study. Analyst Jason Mccarthy has downgraded the stock to Hold, removing it from his model due to the uncertainty surrounding Berubicin’s future. Despite this, the company has another asset, TPI-287, which shows potential in treating CNS tumors. However, the recent reverse stock split and the trial’s failure have put CNS Pharmaceuticals in a challenging position, leaving investors cautious.
Global-e Online is catching the attention of analysts with its high-quality growth story. Analyst James Faucette has upgraded the stock to Buy, citing the company’s conservative guidance and potential benefits from current trade policies. With a price target of $46, Global-e is expected to ride earnings growth higher, especially as investor expectations have been reset to a more achievable level. The company’s strategic positioning and growth prospects make it an attractive option for investors looking for exposure in the e-commerce sector.
Tenet Healthcare is making waves as it undergoes a significant transformation in its business model and balance sheet. Analyst Craig Hettenbach has initiated coverage with a Buy rating and a $165 price target. The company’s shift towards outpatient care and strategic acquisitions position it well for future growth. Despite potential risks from government spending cuts, Tenet’s leadership in the ambulatory surgery center market and improved financial metrics make it a compelling investment opportunity.
Summit Therapeutics is on the rise as analyst Yigal Nochomovitz upgrades the stock to Buy, with a $35 price target. The company’s HARMONi-2 trial shows a promising 70% chance of success, potentially positioning its drug, ivonescimab, as a game-changer in non-small cell lung cancer treatment. While there are concerns about the upcoming HARMONi trial data, the broader outlook for HARMONi-2 remains positive, making Summit Therapeutics a stock to watch for investors interested in the biotech sector.